Most new drugs go on Along with the revenue trajectory set at launch. About 70 % of products that overlook expectations at launch continue on doing this in subsequent years, and about 80 % of products that satisfy or defeat expectations continue on to take action afterward. These courses just take different sorts. “Experimental entry” presen